Published in Cancer Res on September 01, 2005
Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal (2007) 1.48
The Dachshund gene in development and hormone-responsive tumorigenesis. Trends Endocrinol Metab (2009) 1.28
Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res (2007) 1.28
Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res (2010) 1.20
The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling. Cancer Res (2009) 1.14
Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res Treat (2010) 1.10
Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res (2012) 1.08
An inherent role of microtubule network in the action of nuclear receptor. Proc Natl Acad Sci U S A (2006) 1.08
Therapeutic significance of estrogen receptor β agonists in gliomas. Mol Cancer Ther (2012) 1.07
Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway. Mol Cancer Res (2008) 1.07
Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2. Mol Endocrinol (2006) 1.06
Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells. J Cell Biol (2008) 1.05
Significance of PELP1 in ER-negative breast cancer metastasis. Mol Cancer Res (2011) 1.02
Derailed estrogen signaling and breast cancer: an authentic couple. Endocr Rev (2012) 1.01
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells. Mol Endocrinol (2007) 1.01
Retracted Phosphorylation of MNAR promotes estrogen activation of phosphatidylinositol 3-kinase. Mol Cell Biol (2006) 1.01
Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene (2014) 0.98
PELP1: A novel therapeutic target for hormonal cancers. IUBMB Life (2010) 0.98
Extranuclear coactivator signaling confers insensitivity to tamoxifen. Clin Cancer Res (2009) 0.97
PELP1--a novel estrogen receptor-interacting protein. Mol Cell Endocrinol (2008) 0.95
Emerging significance of ER-coregulator PELP1/MNAR in cancer. Histol Histopathol (2007) 0.93
PELP1: a review of PELP1 interactions, signaling, and biology. Mol Cell Endocrinol (2013) 0.92
Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase. PLoS One (2013) 0.90
Regulation of rDNA transcription by proto-oncogene PELP1. PLoS One (2011) 0.88
Comprehensive analysis of recent biochemical and biologic findings regarding a newly discovered protein-PELP1/MNAR. Clin Exp Metastasis (2006) 0.87
ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiol Biomarkers Prev (2008) 0.85
Retracted Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. Cell Mol Life Sci (2014) 0.84
Vitamin C induces periodontal ligament progenitor cell differentiation via activation of ERK pathway mediated by PELP1. Protein Cell (2013) 0.83
Regulation of aromatase induction by nuclear receptor coregulator PELP1. J Steroid Biochem Mol Biol (2009) 0.82
Extranuclear signaling by estrogen: role in breast cancer progression and metastasis. Minerva Ginecol (2010) 0.81
Roles for miRNAs in endocrine resistance in breast cancer. Endocr Relat Cancer (2015) 0.80
PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma. Cancer Res (2014) 0.79
Expression of estrogen receptor co-regulators NCoR and PELP1 in epithelial cells and myofibroblasts of colorectal carcinomas: cytoplasmic translocation of NCoR in epithelial cells correlates with better [corrected] prognosis. Virchows Arch (2008) 0.79
Cytoplasmic PELP1 and ERRgamma protect human mammary epithelial cells from Tam-induced cell death. PLoS One (2015) 0.79
Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer. Cancer Res (2016) 0.76
PELP1: Structure, biological function and clinical significance. Gene (2016) 0.76
Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance. Mol Cancer Ther (2014) 0.76
Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer. PLoS One (2015) 0.76
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst (2004) 6.55
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science (1995) 6.37
Mechanisms of estrogen action. Physiol Rev (2001) 5.97
Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev (2004) 3.74
Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J (1996) 3.53
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell (2004) 3.46
Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev (2001) 2.54
Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol (2003) 2.54
Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem (2000) 2.51
Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol Metab (2002) 2.33
Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell (2004) 2.08
Retracted Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A (2002) 2.01
Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell (2004) 1.93
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res (2003) 1.89
Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J Biol Chem (2001) 1.86
Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol (2002) 1.83
Cell localization, physiology, and nongenomic actions of estrogen receptors. J Appl Physiol (1985) (2001) 1.68
Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res (2004) 1.59
A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology (2000) 1.59
Nongenomic actions of steroid hormones in reproductive tissues. Endocr Rev (1998) 1.57
Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab (2002) 1.47
Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol (2000) 1.45
Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat (2003) 1.44
Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol Endocrinol (2004) 1.44
Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol (2002) 1.43
Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab (2004) 1.41
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat (1993) 1.36
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast (2003) 1.32
Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem (2003) 1.31
Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? J Steroid Biochem Mol Biol (2000) 1.01
Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res (2003) 0.99
Cloning and functional characterization of PELP1/MNAR promoter. Gene (2004) 0.99
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer. Steroids (2000) 0.96
Novel estrogen receptor coregulators and signaling molecules in human diseases. Cell Mol Life Sci (2004) 0.95
Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol (1993) 0.93
Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Anticancer Drugs (1995) 0.86
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med (2011) 6.21
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell (2007) 4.48
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (2005) 3.83
Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity (2006) 2.95
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 2.71
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst (2006) 2.71
Benign breast diseases: classification, diagnosis, and management. Oncologist (2006) 2.64
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol (2010) 2.52
Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1. Nat Cell Biol (2002) 2.45
Pak protein kinases and their role in cancer. Cancer Metastasis Rev (2009) 2.44
MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res (2008) 2.32
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol (2011) 2.32
Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle (2009) 2.31
Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology (2012) 2.23
Modified Trachlight for management of difficult pediatric airway. Paediatr Anaesth (2008) 2.19
SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol Cell (2010) 2.18
Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol (2002) 2.18
Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol (2008) 2.17
Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg (2011) 2.16
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res (2008) 2.15
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J (2003) 2.11
Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res (2005) 2.09
MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Mol Cell Biol (2010) 2.03
The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol (2002) 2.03
Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene (2002) 2.03
Suicide an emerging public health problem: evidence from rural Haryana, India. Indian J Public Health (2013) 2.03
Cystatin C-based glomerular filtration rate estimating equations in early chronic kidney disease. Indian Pediatr (2014) 2.02
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol (2004) 2.00
Metastasis tumor antigens, an emerging family of multifaceted master coregulators. J Biol Chem (2006) 2.00
Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol (2011) 1.96
Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell (2004) 1.93
Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol (2011) 1.93
Taxonomic studies on genus Tetramorium Mayr (Hymenoptera, Formicidae) with report of two new species and three new records including a tramp species from India with a revised key. Zookeys (2012) 1.92
Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol (2007) 1.92
The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A (2004) 1.89
A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature (2002) 1.89
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82
P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J (2002) 1.75
Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res (2006) 1.72
Retracted Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis. J Biol Chem (2010) 1.71
p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem (2003) 1.70
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg (2006) 1.70
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res (2006) 1.67
Retracted Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development (2004) 1.67
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem (2008) 1.66
Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res (2009) 1.66
MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc Natl Acad Sci U S A (2006) 1.66
Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem (2005) 1.65
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res (2005) 1.64
Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res (2013) 1.63
Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging (2014) 1.63
Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. J Pharm Pharm Sci (2006) 1.63
The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol (2004) 1.61
Disseminated tuberculosis masquerading as metastatic breast carcinoma on PET-CT. Clin Nucl Med (2008) 1.61
Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. J Cell Biol (2010) 1.60
Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res (2004) 1.59
Biliary microlithiasis in patients with idiopathic acute pancreatitis and unexplained biliary pain: response to therapy. J Gastroenterol Hepatol (2004) 1.59
Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res (2004) 1.58
P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res (2006) 1.58
RNA sequencing of cancer reveals novel splicing alterations. Sci Rep (2013) 1.57
Retracted Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator. J Biol Chem (2009) 1.56
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res (2005) 1.54
Thyroid scintigraphy in detecting dual ectopic thyroid: a review. Eur J Nucl Med Mol Imaging (2008) 1.54
Noninvasive imaging surrogate of angiogenesis in osteosarcoma. Pediatr Blood Cancer (2010) 1.54
Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest (2012) 1.53
Multicentric mammary carcinoma: evidence of monoclonal proliferation. Cancer (2002) 1.53
Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res (2009) 1.53
HSSB1 and hSSB2 form similar multiprotein complexes that participate in DNA damage response. J Biol Chem (2009) 1.52
AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood (2008) 1.52
Community Perception and Client Satisfaction about the Primary Health Care Services in an Urban Resettlement Colony of New Delhi. Indian J Community Med (2008) 1.52
N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem (2009) 1.52
Nuclear receptor coregulators in cancer biology. Cancer Res (2009) 1.51
Dyke-Davidoff-Masson syndrome. Indian Pediatr (2008) 1.51
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys (2002) 1.51
Hallmarks of mechanochemistry: from nanoparticles to technology. Chem Soc Rev (2013) 1.51
UnPAKing the class differences among p21-activated kinases. Trends Biochem Sci (2008) 1.51
Functional inactivation of a transcriptional corepressor by a signaling kinase. Nat Struct Biol (2003) 1.50
Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer (2005) 1.50
Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal (2007) 1.48
Age-related changes in the metabolic activity and distribution of the red marrow as demonstrated by 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography. Mol Imaging Biol (2007) 1.48